Winst gevend schreef op 27 januari 2022 15:30:
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft FunctionA Phase I/II,Single Center,Randomized,Double-Blind,Placebo-Controlled Study
to Evaluate the Feasibility of Using Human Recombinant C1 Inhibitor(RUCONEST®)
as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
in Recipients of Kidneys From Donation After Cardio-Circulatory Death
Actual Study Start Date : June 21, 2019
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022clinicaltrials.gov/ct2/show/NCT03791476